Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
18 01 2022
18 01 2022
Historique:
received:
25
10
2021
accepted:
05
01
2022
revised:
23
12
2021
entrez:
19
1
2022
pubmed:
20
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the "watch and wait" status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) "watch and wait" or "complete/partial response". The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection.
Identifiants
pubmed: 35042847
doi: 10.1038/s41408-022-00608-6
pii: 10.1038/s41408-022-00608-6
pmc: PMC8764505
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
ID : PRIN 2017
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
ID : Aging Project
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
ID : PRIN 2017
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
ID : Aging Project
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG 21744
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : 5 x 1000 No. 21198
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RF-2018-12365790
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Blood. 2021 Nov 4;138(18):1768-1773
pubmed: 34297826
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285
Lancet Haematol. 2021 Aug;8(8):e542-e544
pubmed: 34224667
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Blood Adv. 2021 Aug 24;5(16):3053-3061
pubmed: 34387648
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Cancer Discov. 2021 Aug;11(8):1982-1995
pubmed: 34011563
Blood Cancer J. 2021 Aug 10;11(8):142
pubmed: 34376633
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
Blood Cancer J. 2021 Jul 30;11(7):136
pubmed: 34330895
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Leukemia. 2021 Jan;35(1):289-292
pubmed: 33299142
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Med Virol. 2021 Dec;93(12):6444-6446
pubmed: 34260066
JAMA Oncol. 2021 Nov 1;7(11):1714-1716
pubmed: 34379085
Viruses. 2021 Nov 12;13(11):
pubmed: 34835076
Leukemia. 2021 Dec;35(12):3573-3577
pubmed: 34023850
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Cancer Cell. 2021 Feb 8;39(2):257-275.e6
pubmed: 33476581
Hematol Oncol. 2021 Aug;39(3):428-431
pubmed: 33951220
Br J Haematol. 2022 Jan;196(2):362-367
pubmed: 34490627
J Med Virol. 2021 Jul;93(7):4585-4591
pubmed: 33595119
Br J Haematol. 2021 Nov;195(3):371-377
pubmed: 34272724
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cancer Cell. 2021 Aug 9;39(8):1045-1047
pubmed: 34242573
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
Cancer Cell. 2021 Aug 9;39(8):1028-1030
pubmed: 34242572
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035
Vaccines (Basel). 2021 Mar 10;9(3):
pubmed: 33801831
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503290
Blood Cancer J. 2021 Aug 2;11(8):138
pubmed: 34341335